Huhtamaki invests in new fiber packaging capacity in South Africa
HUHTAMÄKI OYJ PRESS RELEASE 27.5.2021 AT 08:00
Huhtamaki invests in new fiber packaging capacity in South Africa
Huhtamaki, a global key advanced manufacturer of sustainable packaging solutions, is setting up a new manufacturing unit in KwaZulu-Natal in South Africa to serve its existing and new egg packaging customers in the KwaZulu-Natal area with a broad range of locally produced packaging solutions. The new facility will be located close to one of South Africa’s main export ports, enabling competitive exports of egg packaging for customers across East Africa.
“The addition of a unit in KwaZulu-Natal is an important addition to our fiber packaging footprint in South Africa not only providing efficiencies in our service to customers in South Africa but an additional benefit in terms of proximity to a major port which will drive access to markets across East Africa. The new facility sets us up to better meet the growth of the fiber packaging sector and future demand for sustainable packaging. It also strengthens our position in the region significantly,” says Eric Le Lay, President, Fiber Foodservice Europe-Asia-Oceania.
This investment underlines Huhtamaki´s strong commitment to the growing customer base in South Africa and East Africa, as the addition of several new lines allow a significant increase in capacity. Manufacturing operations are expected to begin during the fourth quarter in 2021 and the facility is expected to employ approximately 30 employees when fully operational.
Huhtamaki has operated in South Africa since 2000. The company currently employs approximately 530 people across four manufacturing units and manufactures fiber packaging for eggs and fruits, foodservice packaging, and flexible packaging. Huhtamaki South Africa has a level 4 rating in the B-BBEE (Broad-Based Black Economic Empowerment) program.
For further information, please contact:
Calle Loikkanen, Head of Investor Relations and Financial Communications, tel. +358 10 686 7125
Katariina Hietaranta, Head of Media Relations, tel. +358 10 686 7863
Huhtamaki is a key global provider of sustainable packaging solutions for consumers around the world, enabling wellbeing and convenience. Our innovative products protect on-the-go and on-the-shelf food and beverages, ensuring hygiene and safety, and help prevent food waste. We embed sustainability in everything we do. We are committed to achieving carbon neutral production and designing all our products to be recyclable, compostable or reusable by 2030.
We are a participant in the UN Global Compact and as of 2020, we received an MSCI ESG Rating of A, on a scale of AAA ─ CCC. To play our part in managing climate change, we have committed to set science-based targets through the Science Based Targets initiative. Huhtamaki has been awarded the Silver medal by EcoVadis for performance in sustainability.
With 100 years of history and a strong Nordic heritage we operate in 36 countries and 81 sites around the world. Our values Care Dare Deliver guide our decisions and help our team of 18,1200 employees make a difference where it matters. Our 2020 net sales totaled EUR 3.3 billion. Huhtamaki Group is headquartered in Espoo, Finland and our parent company, Huhtamäki Oyj, is listed on Nasdaq Helsinki Ltd. Find out more about how we are protecting food, people and the planet on www.huhtamaki.com.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Data analysis from dLab to boost the digitalization for Karlskoga Energi & Miljö24.6.2021 09:55:00 CEST | Press release
Regional utilities company Karlskoga Energi & Miljö AB has been using the smart data analytics solution from cleantech company Dlaboratory Sweden AB (publ) since 2020. A useful solution for avoiding power outages and identifying faults, dLab’s system is the starting point for the energy company’s digitalization journey. Energy company Karlskoga Energi & Miljö with its subsidiary Karlskoga Elnät has around 15 000 customers along a 1 700 km grid in the middle of the beautiful region of Värmland. Digitalization is a high priority throughout the organization, whether it means providing fiber optics for consumers, or the dInsight Analytics Platform from dLab. -The solution from dLab pushes us to work in a completely new way; from monitoring and analysis to becoming proactive, using data to prevent, rather than fix a problem. This requires new knowledge in the organization, but also a new way of working, says Jimmy Lundberg, Head of Distribution at Karlskoga Elnät. The company chose dLab’s s
Nokia launches next-generation AirScale 5G portfolio powered by ReefShark technology24.6.2021 09:00:00 CEST | Press release
Press Release Nokia launches next-generation AirScale 5G portfolio powered by ReefShark technology Nokia’s new, industry-leading 5G portfolio covers baseband, radio, and massive MIMO antennas offering huge 5G capacity, coverage, and easy deploymentIntroduces industry’s lightest massive MIMO units at 17kg enabling simplified deployments and faster time to marketNokia’s new comprehensive range of products are powered by Nokia’s latest generation of ReefShark chipsets Nokia’s extended Single RAN accelerates 5G rollouts and cuts overall RAN Total Cost of Ownership 24 June 2021 Espoo, Finland – Nokia today announced the global launch of its latest range of industry-leading AirScale 5G products covering baseband, remote radio heads, and massive MIMO active antennas with digital beamforming. The innovative solutions are powered by the latest generation of Nokia’s ReefShark System-on-Chip (SoC) chipsets and deliver the highest capacity and network performance while enabling efficient deploymen
Huvepharma Announces the Indicative Price Range, Publication of the Prospectus and Start of the Offer Period of Planned IPO24.6.2021 08:15:39 CEST | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. This announcement is an advertisement for the purposes of the Prospectus Regulation EU 2017/1129 and underlying legislation, relating to the launch of the Offer (as defined below) by the Company and the proposed Admission (as defined below). This announcement does not constitute a prospectus. This announcement is for information purposes only and is not intended to constitute, and should not be construed as, an offer to sell or a solicitation of any offer to buy Shares (as defined below) in any jurisdiction, including the United States, Canada, Australia or Japan. Further details about the Offer and the Admission is included in the Prospectus (as defined below). The Prospectus has today been approved by the Netherlands Authority for the Financial Markets (Stich
FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD)24.6.2021 07:00:00 CEST | Press release
If approved, PDS would be the first and only eye implant with continuous drug delivery that offers people living with nAMD an alternative to frequent eye injectionsA pivotal study showed PDS extends time between treatments up to six months for more than 98% of patients and provides vision outcomes equivalent to monthly ranibizumab injectionsThe European Medicines Agency has also validated the PDS Marketing Authorisation Application in nAMD Basel, 24 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD). Neovascular AMD is a leading cause of blindness for people aged 60 and over and impacts approximately 20 million people worldwide.1,2,3 If approved, PDS would be a first-of-its-kind therapeutic approach, offering pe
ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting24.6.2021 07:00:00 CEST | Press release
- Data from Phase 3 study ofYselty® (linzagolix) for the treatment of uterine fibroids to be discussed in an oral presentation; Top-line data from pilot study of Yselty for the treatment of severe adenomyosis to be presented in an ePoster- -Data from IMPLANT1 Phase 2 study of nolasiban for uterine contractility of IVF patients prior to embryo transfer to be presented in an ePoster - GENEVA, Switzerland and BOSTON– June 24, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of data from two of its clinical development programs at the European Society of Human Reproduction and Embryology (ESHRE) Virtual 37th Annual Meeting, being held June 26 - July 1, 2021. Details of the presentations for the Yseltyprogram are as follows: Title: Long-Term Secondary Efficacy of Linzagolix for Heavy Menstrual Bleeding (HMB) Due to Uterine Fibroids (UF): 52-Week Res
Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group24.6.2021 07:00:00 CEST | Press release
Acquires all royalty rights to Maxigesic® IV Assumes sole responsibility for HY-075 and HY-038 – future profit split lapses Gains higher net profit margin for Fusidic Acid Cream in Canada Hyloris CEO and CBDO to resign from the Board of Directors of Alter Pharma Liège, Belgium – 24June 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today announces that it has successfully renegotiated and unwound its earlier license agreements with the Alter Pharma Group. Hyloris will pay the Alter Pharma Group a total lump sum of €5.25 million plus €0.5 million potential earn-out, thereby waiving any further future financial obligations towards the Alter Pharma Group. Hyloris Pharmaceuticals and the Alter Pharma Group have amended and unwound the earlier license agreements as follows: The patent and knowhow license agreement in relation to Maxigesic IV has b
Enento Group makes a strategic investment to add a unique Sales Intelligence service offering by acquiring a part of Goava Sales Intelligence AB with possibility to take majority24.6.2021 07:00:00 CEST | Press release
ENENTO GROUP PLC, STOCK EXCHANGE RELEASE ON 24 JUNE 2021 AT 8.00 A.M. EEST Enento Groupmakes a strategic investment to add a uniqueSales Intelligence service offering byacquiring apart of Goava Sales Intelligence AB with possibility to take majority Enento Group Plc has signed an agreement to acquire part of and become the largest shareholder of the Swedish sales intelligence services company Goava Sales Intelligence AB by subscribing to new preference shares in the company. Within the agreement, Enento in the first stage on 24 June 2021 acquires a 38,3 % (35,1 % fully diluted) shareholding in the company, and at the same time agrees to complete subsequent preference share subscriptions provided that the company fulfills certain preconditions laid out in the business plan, as well as acquires a purchase option to acquire all outstanding shares in the company after a mutually agreed business plan period ending in year 2024 and aiming at gaining a significant market position for the serv